Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Clinical Study of All-Trans Retinoic Acid in Combination With a PD-1 Inhibitor in Patients With EGFR-Mutant Non-Small Cell Lung Cancer After Acquired Resistance to a Third-Generation EGFR Tyrosine Kinase Inhibitor

NCT07842887 is registered in ClinicalTrials.gov with Cancer Institute and Hospital, Chinese Academy of Medical Sciences as lead sponsor.

NCT NCT07842887
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07842887 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Clinical Study of All-Trans Retinoic Acid in Combination With a PD-1 Inhibitor in Patients With EGFR-Mutant Non-Small Cell Lung Cancer After Acquired Resistance to a Third-Generation EGFR Tyrosine Kinase Inhibitor
Lead sponsor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase
Phase 1
Overall status
Not yet recruiting
Start date
October 1, 2026
Completion date
October 10, 2028
Enrollment
24 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

egfr-tki-resistant non-small cell lung cancer